Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 103, Issue 6, 2006, Pages 1888-1893

  Tovar, Christian ^a   Rosinski, James ^a   Filipovic, Zoran ^a   Higgins, Brian ^a   Kolinsky, Kenneth ^a   Hilton, Holly ^a   Zhao, Xiaolan ^a   Vu, Binh T ^a   Qing, Weiguo ^a   Packman, Kathryn ^a   Myklebost, Ola ^b   Heimbrook, David C ^a   Vassilev, Lyubomir T ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Apoptosis; Cell cycle; Inhibitor; Tumor; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; NUTLIN 3; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDM2 INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL CYCLE ARREST; CONTROLLED STUDY; DNA MICROARRAY; EMBRYO; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MICE; MICE, NUDE; NEOPLASMS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 32444449180     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0507493103     Document Type: Article

References (34)

1. Levine, A. J. (1997) Cell 88, 323-331.
2. Vogelstein, B., Lane, D. & Levine, A. J. (2000) Nature 408, 307-310.
3. Harris, S. L. & Levine, A. J. (2005) Oncogens 24, 2899-2908.
4. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. C. (1991) Science 253, 49-53.
5. Hainaut, P. & Hollstein, M. (2000) Adv. Cancer Res. 77, 81-137.
6. Picksley, S. M. & Lane, D. P. (1993) BioEssays 15, 689-690.
7. Lane, D. P. (1999) Br. J. Cancer 80, Suppl. 1, 1-5.
8. Freedman, D. A., Wu, L. & Levine, A. J. (1999) Cell Mol. Life Sci. 55, 96-107.
9. Chene, P. (2003) Nat. Rev. Cancer 3, 102-109.
10. Honda, R., Tanaka, H. & Yasuda, H. (1997) FEBS Lett. 420, 25-27.
11. Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. (1992) Cell 69, 1237-1245.
12. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) Science 303, 844-848.
13. Momand, J., Wu, H. & Dasgupta, G. (2000) Gene 242, 15-29.
14. Ashkroft, M. & Vousden, K. (1999) Oncogene 18, 7637-7643.
15. Michael, D. & Oren, M. (2003) Semin. Cancer Biol. 13, 49-58.
16. Bond, G. L., Hu, W. & Levine, A. J. (2005) Curr. Cancer Drug Targets 5, 3-8.
17. Vousden, K. H. & Prives, C. (2005) Cell 120, 7-10.
18. Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. (1995) Nature 378, 203-206.
19. Zhao, R., Gish, K., Murphy, M., Yin, Y., Notterman, D., Hoffman, W. H., Tom, E., Mack, D. H. & Levine, A. J. (2000) Genes Dev. 14, 981-993.
20. Kannan, K., Amariglio, N., Rechavi, G., Jakob-Hirsch, J., Kela, I., Kaminski, N., Getz, G., Domany, E. & Givol, D. (2001) Oncogene 20, 2225-2234.
21. Kannan, K., Kaminski, N., Rechavi, G., Jakob-Hirsch, J., Amariglio, N. & Givol, D. (2001) Oncogens 20, 3449-3455.
22. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. & Vogelstein, B. (1993) Cell 75, 817-825.
23. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W. & Vogelstein, B. (1998) Science 282, 1497-1501.
24. Schuler, M. & Green, D. R. (2005) Trends Genet. 21, 182-187.
25. Steensma, D. P., Timm, M. & Witzig, T. E. (2003) Methods Mol. Med. 85, 323-332.
26. Perego, P., Corna, E., De Cesare, M., Gatti, L., Polizzi, D., Pratesi, G., Supino, R. & Zunino, F. (2001) Curr. Med. Chem. 8, 31-37.
27. Berner, J.-M., Forus, A., El Kahloun, A., Meltzer, P. S., Fodstad, Ø. & Myklebost, O. (1996) Genes Chromosomes Cancer 17, 254-259.
28. Thompson, T., Tovar, C., Yang, H., Carvajal, D., Vu, B. T., Xu, Q., Wahl, G. M., Heimbrook, D. C. & Vassilev, L. T. (2004) J. Biol. Chem. 279, 53015-53022.
29. Vousden, K. H. & Lu, X. (2002) Nat. Rev. Cancer 2, 594-604.
30. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. & Beach, D. (1993) Nature 366, 701-704.
31. Satyamoorthy, K., Chehab, N. H., Waterman, M. J., Lien, M. C., El-Deiry, W. S., Herlyn, M. & Halazonetis, T. D. (2000) Cell Growth Differ. 11, 467-474.
32. Oren, M. (2003) Cell Death Differ. 10, 431-442.
33. Momand, J., Jung, D., Wilczynski, S. & Niland, J. (1998) Nucleic Acids Res. 26, 3453-3459.
34. Yang, H., Filipovic, Z., Brown, D., Breit, S. N. & Vassilev, L. T. (2003) Mol. Cancer Ther. 2, 1023-1029.